Global Trastuzumab Injection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Trastuzumab Injection Market Research Report 2024
Trastuzumab is a targeted cancer drug and is also known by other names such as Herceptin, Herzuma and Ontruzant. It is a treatment for early and advanced breast cancer, advanced stomach cancer and cancer of where the food pipe joins your stomach (gastro oesophageal junction). Trastuzumab injection products are used with other medications or after other medications have been used to treat a certain type of breast cancer that has spread to other parts of the body. Trastuzumab injection products are also used during and after treatment with other medications to decrease the chance that a certain type of breast cancer will return. Trastuzumab injection products are also used with other medications to treat certain types of stomach cancer that have spread to other parts of the body. Trastuzumab is in a class of medications called monoclonal antibodies. It works by stopping the growth of cancer cells.
According to Mr Accuracy reports’s new survey, global Trastuzumab Injection market is projected to reach US$ 1098.8 million in 2029, increasing from US$ 775 million in 2022, with the CAGR of 5.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Trastuzumab Injection market research.
Key manufacturers engaged in the Trastuzumab Injection industry include Pfizer, Roche, Celltrion, Amgen, Samsung Bioepsis, Mylan, Glenmark, AstraZeneca and Remegen Co., Ltd., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Trastuzumab Injection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Trastuzumab Injection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Trastuzumab Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
Roche
Celltrion
Amgen
Samsung Bioepsis
Mylan
Glenmark
AstraZeneca
Remegen Co., Ltd.
Hisun Biopharmaceutical
Shanghai Henlius Biotech
Segment by Type
60 mg
150 mg
440 mg
Others
Hospitals
Clinics
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Trastuzumab Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Trastuzumab Injection market is projected to reach US$ 1098.8 million in 2029, increasing from US$ 775 million in 2022, with the CAGR of 5.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Trastuzumab Injection market research.
Key manufacturers engaged in the Trastuzumab Injection industry include Pfizer, Roche, Celltrion, Amgen, Samsung Bioepsis, Mylan, Glenmark, AstraZeneca and Remegen Co., Ltd., etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Trastuzumab Injection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Trastuzumab Injection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Trastuzumab Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Roche
Celltrion
Amgen
Samsung Bioepsis
Mylan
Glenmark
AstraZeneca
Remegen Co., Ltd.
Hisun Biopharmaceutical
Shanghai Henlius Biotech
Segment by Type
60 mg
150 mg
440 mg
Others
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Trastuzumab Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices